- monatlichErscheinungsrhythmus
- 16 mintypische Länge
- 26. Okt.letzte Folge
Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.
Folgen
Iberdomide, daratumumab, and dexamethasone in relapsed or refractory multiple myeloma with Professor Lonial
Iberdomide, daratumumab, and dexamethasone as a treatment option for patients with relapsed or refractory multiple myeloma. Click here the full article: S1470-2045(26)00450-X
Accelerating equitable cancer genomics and precision oncology with Raffaella Casolino and Mark Lawler
In this special episode, Dr Cheryl Lai, Acting Deputy Editor at The Lancet Oncology, is joined by Dr Raffaella Casolino (University of Glasgow, UK; International Cancer Genome Consortium - Accelerating Research in Genomic Oncology) and Prof
Tumour-infiltrating lymphocytes in breast cancer with Professor Sherene Loi
Professor Sherene Loi and the International Immuno-Oncology Biomarker Working Group on tumour-infiltrating lymphocytes as breast cancer biomarkers. Two Articles cover AI and digital pathology scoring methods and a Review examines integratin
5-year quality of life study of the SUPREMO trial examining chest wall radiotherapy in patients with intermediate-risk breast cancer with Professor Galina Velikova
5-year quality of life (QOL) substudy of the SUPREMO trial examining the effects of chest wall radiotherapy versus no chest wall radiotherapy after mastectomy in patients with intermediate-risk breast cancer. The data will put patients in a
Hans Merks on European guidelines for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma
Imaging is central to osteosarcoma and Ewing sarcoma diagnosis and treatment, yet no international consensus defines optimal modalities or schedules to date. Hans presents harmonised European recommendations for the imaging of bone sarcomas
Hedvig Hricak and Zachary Ward on Cancer workforce—a global crisis: a Lancet Oncology Commission
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Hedvig Hricak (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and Dr Zachary Ward (Harvard TH Chan School of Public Health, Boston, MA, USA) to discuss Cancer w
Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the ran
James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE). Clic
Ali Landman on the European Congress of Radiology 2026
Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal and Ali's highlights in oncological imaging
Kayleigh Bhangdia on breast cancer GBD study 2023
Kayleigh Bhangdia discusses the latest GBD breast cancer study data, telling the audience about epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally for 204 countries fr
Dylan Graetz and Erica Kaye on qualitative research in oncology
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz (Department of Oncology and Department of Global Pediatric Medicine, St Jude Children’s Research Hospital) and Dr Erica Kaye (Department of Oncology, St Jude C
Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers
Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak (Division of Cancer Prevention and Control, The Ohio State University) and Dr Marissa Baker (Department of Environmental & Occupational Health Science, Universi
Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3
Dr Andre Pfob (Department of Obstetrics & Gynecology, Heidelberg University Hospital) and Prof Peter Dubsky (Faculty of Health Sciences and Medicine, University of Lucerne) discuss their Review entitled The Lucerne Toolbox 3: digital health
Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission
Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care. Click here to read the full Commission: The huma
Matthias Preusser on the phase 2 TUXEDO-3 trial
Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastase
Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer
Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan,
Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas
Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expr
Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer
Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Dr Jinming Li, from the Department of Colorectal Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China to discuss his international, multicohort, observational st
Abdalla Awidi on cancer control in the Middle East
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Professor Abdalla Awidi (Founder and Director of Stem Cell Therapy Center, University of Jordan, Amman, Jordan) to discuss The Lancet Oncology's Cancer control in the Middle E
ASCO 2025 Debrief
Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights fro
Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial)
Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial. EBIN was an open-label, randomised, controlled, phase 2 trial conducted at 37
Richard Bryant on transperineal vs transrectal biopsy for prostate cancer
Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Richard Bryant from the University of Oxford to discuss the TRANSLATE trial. This extensive UK-based randomised controlled trial compares the use of local anaest
Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)
Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Random
Ariana Znaor on cancer surveillance in the Eastern Mediterranean region
Ariana Znaor (Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France) discusses her Review on cancer surveillance in the Eastern Mediterranean Region: a 10-year IARC-WHO EMRO collaboration. Tell us what you th
Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials
Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical tri
Yannick Romero on the changing landscape of national cancer control plans
Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership. Read the full article: htt
M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries
Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discuss their Series on Ca
Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma
Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral
Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination
Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations. Read the full Article: https://www.thel
May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics
May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Au
